Peritoneal fibrosis
The peritoneal dialysis (PD) is one way of renal function's substitution and as a treatment, it covers more than 100,000 patients with stage V chronic kidney disease worldwide, so the prevalence rate ranges from 10 to 15% of the dialysis population. The biggest obstacles to the long-term therap...
| Main Author: | |
|---|---|
| Format: | Article |
| Language: | Spanish |
| Published: |
Asociación Regional de Diálisis y Trasplantes Renales de Capital Federal y Provincia de Buenos Aires
2017-04-01
|
| Series: | Revista de Nefrología, Diálisis y Trasplante |
| Subjects: | |
| Online Access: | http://www.revistarenal.org.ar/index.php/rndt/article/view/26 |
| Summary: | The peritoneal dialysis (PD) is one way of renal function's substitution and as a treatment, it covers more than 100,000 patients with stage V chronic kidney disease worldwide, so the prevalence rate ranges from 10 to 15% of the dialysis population. The biggest obstacles to the long-term therapy are infections and disorders suffered by the peritoneal membrane when exposed to dialytic solutions that generate loss of dialysis capacity in both diffusion and ultrafiltration. These changes can affect almost 50% of patients on dialysis. They include progressive fibrosis, angiogenesis and vascular degeneration. In a small percentage fibrosis occurs in the visceral peritoneum leading to their worst performance: encapsulating peritoneal sclerosis, with a high mortality rate. Being acquainted with the pathophysiology of these disorders, causes changes in the use of therapy to prevent the appearance, progression to fibrosis and thus reduce the drop-out of the technique due to peritoneal exhaustion. In this article some of the mechanisms of production and possible measures to reduce appearance of peritoneal fibrosis will be reviewed. |
|---|---|
| ISSN: | 0326-3428 2346-8548 |